Auxilium Pharma to Present XIAFLEX Data at Urology Meeting
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced presentations from multiple trials evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be presented at the upcoming American Urological Association (AUA) Meeting being held in Orlando, Florida on May 16-21, 2014.
Podium presentations on XIAFLEX will include new analyses from the pivotal Phase 3 IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials evaluating XIAFLEX for the treatment of PD. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a penile curvature deformity of 30 degrees or greater at the start of therapy.
Data to be presented on XIAFLEX:
Development of an Intralesional Injection Simulator Model of Peyronie's Disease Treatment Podium session 22: Sexual Function/Dysfunction/Andrology: Peyronie's Disease, Monday, May 19, 2014 from 1:00 - 3:00 p.m. ET, abstract 14-7086 Collagenase Clostridium Histolyticum Degrades Type I and II Collagen While Sparing Type IV Collagen In Vitro in Peyronie's plaque Explants Podium session 22: Sexual Function/Dysfunction/Andrology: Peyronie's Disease, Monday, May 19, 2014 from 1:00 - 3:00 p.m. ET, abstract 14-6872 Effect of Time Between First and Second Injection of Collagenase Clostridium Histolyticum on Penile Curvature Deformity During the First Treatment Cycle of Men With Peyronie's Disease Podium session 22: Sexual Function/Dysfunction/Andrology: Peyronie's Disease, Monday, May 19, 2014 from 1:00 - 3:00 p.m. ET, abstract 14-6421 Meaningful Change in Peyronie's Disease Following Treatment With Collagenase Clostridium Histolyticum: Results From Two Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies Podium session 22: Sexual Function/Dysfunction/Andrology: Peyronie's Disease, Monday, May 19, 2014 from 1:00 - 3:00 p.m. ET, abstract 14-6631 Auxilium's partner, VIVUS, Inc., will also be presenting data at AUA examining the onset of action of STENDRA™ (avanafil) in mild to severe erectile dysfunction.
About XIAFLEX XIAFLEX (collagenase clostridium histolyticum, or CCH) is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord and for the treatment of adult men with PD with a palpable plaque and penile curvature deformity of at least 30 degrees at the start of therapy in the U.S. XIAFLEX consists of a combination of two subtypes of collagenase, derived from Clostridium histolyticum. Together, the collagenase sub-types are thought to work synergistically to break the bonds of the triple helix collagen structure. XIAFLEX has been granted Orphan status in the U.S. by the FDA for DC and PD.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.